[go: up one dir, main page]

WO2005060361A3 - Formulations pharmaceutiques pour l'itraconazole - Google Patents

Formulations pharmaceutiques pour l'itraconazole Download PDF

Info

Publication number
WO2005060361A3
WO2005060361A3 PCT/KR2004/003422 KR2004003422W WO2005060361A3 WO 2005060361 A3 WO2005060361 A3 WO 2005060361A3 KR 2004003422 W KR2004003422 W KR 2004003422W WO 2005060361 A3 WO2005060361 A3 WO 2005060361A3
Authority
WO
WIPO (PCT)
Prior art keywords
itraconazole
pharmaceutical formulations
pharmaceutical composition
block copolymer
relates
Prior art date
Application number
PCT/KR2004/003422
Other languages
English (en)
Other versions
WO2005060361A2 (fr
Inventor
Hye-Jeong Yoon
Min Hyo Seo
Jeong-Kyung Kim
Original Assignee
Samyang Corp
Hye-Jeong Yoon
Min Hyo Seo
Jeong-Kyung Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Corp, Hye-Jeong Yoon, Min Hyo Seo, Jeong-Kyung Kim filed Critical Samyang Corp
Publication of WO2005060361A2 publication Critical patent/WO2005060361A2/fr
Publication of WO2005060361A3 publication Critical patent/WO2005060361A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)

Abstract

La présente invention a trait à une composition pharmaceutique contenant en tant que principe actif, l'itraconazole. Plus particulièrement, la présente invention a trait à une composition pharmaceutique comportant de l'itraconazole, un dérivé de l'acide polylactique, et un copolymère bloc amphiphile. Le dérivé de l'acide polylactique peut être combiné avec un ion métallique au niveau du terminal d'acide carboxylique, et le copolymère bloc forme des micelles et des nanoparticules dans un milieu aqueux.
PCT/KR2004/003422 2003-12-23 2004-12-23 Formulations pharmaceutiques pour l'itraconazole WO2005060361A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030095349A KR20050064075A (ko) 2003-12-23 2003-12-23 이트라코나졸을 유효성분으로 하는 약학적 조성물
KR10-2003-0095349 2003-12-23

Publications (2)

Publication Number Publication Date
WO2005060361A2 WO2005060361A2 (fr) 2005-07-07
WO2005060361A3 true WO2005060361A3 (fr) 2005-09-15

Family

ID=34709248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2004/003422 WO2005060361A2 (fr) 2003-12-23 2004-12-23 Formulations pharmaceutiques pour l'itraconazole

Country Status (2)

Country Link
KR (2) KR20050064075A (fr)
WO (1) WO2005060361A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298676A1 (en) * 2005-10-26 2009-12-03 Michael Meier Unimolocular Micelles Containing Metal Nanoparticles and their Use as Catalyst for Synthesis of Carbon-Carbon-Bonds
KR100858508B1 (ko) * 2005-12-23 2008-09-12 주식회사 삼양사 아졸계 항진균제를 포함하는 조성물 및 그의 제조방법
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
KR101267813B1 (ko) 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
US20170181979A1 (en) * 2014-03-31 2017-06-29 Shimadzu Corporation Process for producing nanoparticles
KR102184768B1 (ko) * 2018-12-31 2020-11-30 중앙대학교 산학협력단 혼합 고분자 미셀 조성물 및 이의 용도
CN111888523A (zh) * 2020-09-08 2020-11-06 尹振宇 一种用于改善肌肤的聚乳酸凝胶的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0605933A1 (fr) * 1992-12-24 1994-07-13 PHARMATECH GmbH Procédé de préparation de pseudo-latex et micro- ou nanoparticules et compositions les contenant
US6365173B1 (en) * 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
JP2002138036A (ja) * 2000-08-24 2002-05-14 Santen Pharmaceut Co Ltd 薬物放出制御システム
WO2002045689A1 (fr) * 2000-12-07 2002-06-13 Samyang Corporation Composition permettant la libération prolongée de médicaments hydrophobes, et procédé d'élaboration correspondant
WO2003033592A1 (fr) * 2001-10-18 2003-04-24 Samyang Corporation Composition de micelle polymere a la stabilite amelioree
WO2003033593A1 (fr) * 2001-10-18 2003-04-24 Samyang Corporation Derives d'acide polylactique biodegradables sensibles au ph formant des micelles polymeres et utilisations de ceux-ci pour l'administration de medicaments faiblement hydrosolubles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0605933A1 (fr) * 1992-12-24 1994-07-13 PHARMATECH GmbH Procédé de préparation de pseudo-latex et micro- ou nanoparticules et compositions les contenant
US6365173B1 (en) * 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
JP2002138036A (ja) * 2000-08-24 2002-05-14 Santen Pharmaceut Co Ltd 薬物放出制御システム
WO2002045689A1 (fr) * 2000-12-07 2002-06-13 Samyang Corporation Composition permettant la libération prolongée de médicaments hydrophobes, et procédé d'élaboration correspondant
WO2003033592A1 (fr) * 2001-10-18 2003-04-24 Samyang Corporation Composition de micelle polymere a la stabilite amelioree
WO2003033593A1 (fr) * 2001-10-18 2003-04-24 Samyang Corporation Derives d'acide polylactique biodegradables sensibles au ph formant des micelles polymeres et utilisations de ceux-ci pour l'administration de medicaments faiblement hydrosolubles

Also Published As

Publication number Publication date
WO2005060361A2 (fr) 2005-07-07
KR20060129289A (ko) 2006-12-15
KR20050064075A (ko) 2005-06-29
KR100834148B1 (ko) 2008-06-02

Similar Documents

Publication Publication Date Title
CA2535364A1 (fr) Nanoparticules d'acide hyaluronique
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
WO2001058412A3 (fr) Extraits de residus de la production de vin
WO2005105043A3 (fr) Compositions pharmaceutiques
WO2007014124A3 (fr) Formes posologiques et preparations a charge medicamenteuse elevee
ZA200301813B (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
AU3541901A (en) Galenic formulation
WO2004026231A3 (fr) Preparation d'agents lipophiles
WO2007100466A3 (fr) Formules de carvedilol nanoparticulé
EP1312366A8 (fr) Compositions pharmaceutiques aqueuses
WO2007066150A3 (fr) Administration de principes actifs par voie transdermique pour l'obtention d'un effet systemique
WO2008128775A3 (fr) Composition pharmaceutique stabilisée contenant de la prégabaline
WO2003032941A3 (fr) Combinaison de principes actifs cosmetique et/ou dermatologique
AU2001262011A1 (en) A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component
WO2004062561A3 (fr) Compositions pharmaceutiques
WO2007027314A3 (fr) Compositions anti-inflammatoires et leurs methodes d'utilisation
WO2000054754A3 (fr) Composition comprenant de l'isoquercetine et de l'acide ascorbique a liberation prolongee
WO2005007117A3 (fr) Formulation pharmaceutique et procede de traitement de troubles gastro-intestinaux lies a l'acidite
IL174336A0 (en) Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
WO2006129237A3 (fr) Nouveaux derives d'amide d'acide piperidine carboxylique
EP1561457A3 (fr) Composition cosmétique à pouvoir d' hydratation cutanèe de longue durée
WO2006127319A3 (fr) Formulations d'acide suberoylanilide hydroxamique et leurs procedes de production
WO2005060361A3 (fr) Formulations pharmaceutiques pour l'itraconazole
WO2008087323A8 (fr) Forme galenique pour l'administration par voie trans-muqueuse de paracetamol
UA93355C2 (ru) Композиция субероиланилид-гидроксаминовой кислоты и способы ee получения

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 1020067014798

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020067014798

Country of ref document: KR

122 Ep: pct application non-entry in european phase